Your oncologist in Vienna
OA Priv.-Doz.
Dr. Hossein Taghizadeh, PhD MSc
Specialist in internal medicine, hematology, internal oncology
Specialist in internal medicine,
Hematology, internal oncology
Your oncologist in Vienna
OA Priv.-Doz.
Dr. Hossein Taghizadeh, PhD MSc
Specialist in internal medicine,
Hematology, internal oncology
Welcome to my website!
I look forward to welcoming you to my oncology practice in Vienna!
As a specialist in hematology and oncology, I can advise you on new diagnostic methods and modern, evidence-based cancer therapies.
Cancer is not only a medical challenge, but also affects the emotional and personal level of the patient. That is why I attach great importance to standing by your side with my knowledge and experience and accompanying you through this time with empathy and understanding.
In addition to my work as a senior physician at St. Pölten University Hospital, I teach as a lecturer in oncology at Karl Landsteiner Private University in order to pass on my knowledge to the next generation of doctors.
I would be happy to provide you with the best possible support.
Yours, Hossein Taghizadeh
About me
Clinical career
| 2010-2016 | Human medicine studies at the Medical University of Vienna (MUW) |
| 2018 -2021 | Resident at the University Clinic for Internal Medicine I of the MUW |
| 2021-2024 | Resident at the Oncology Department of the University Hospital St. Pölten |
| Since July 2024 | Senior consultant in oncology at the University Hospital St. Pölten with a focus on gastrointestinal oncology and urogenital oncology |
Academic career
| 2017 -2021 | PhD in the doctoral program in oncology (N094) at the Department of Internal Medicine I of the MUW – Title of the dissertation: “Characteristics and therapy of advanced cancer diseases” |
| 2021-2023 | Postdoc in the working group of Professor Dr. Sibilia at the Center for Cancer Research of the MUW |
| 2022-2023 | Master’s program “Molecular Oncology”
at the Centro de Estudios Biosanitarios (CEB), Madrid, Spain |
| 22.11.2023 | Habilitation in the field of “Clinical Oncology” at the Medical University of Vienna to obtain the Venia docendi and the title of Privatdozent (PD). |
Memberships
- European Pancreatic Club (EPC)
- American Association for Cancer Research (AACR)
- American Society of Clinical Oncology (ASCO)
- European Society of Medical Oncology (ESMO)
- Austrian Society of Hematology and Oncology (OeGHO)
- European Society of Digestive Oncology (ESDO)
- Karl Landsteiner Society - Institute of Nephrology and Hematooncology
- Austrian Breast and Colorectal Cancer Study Group (ABCSG) - Colorectal Branch
Scientific activity | Lectures | Publications
Research focus: Gastrointestinal and urogenital oncology
Lectures at national and international congresses and training events
Member of the PhD curriculum team for the development of the doctoral program “Tumor Biology” at Karl Landsteiner Private University
Selection of first authorships
-
Immunotherapy in the Management of Penile Cancer-A Systematic Review
Taghizadeh H., Fajkovic H. Cancers 2025, 17, 883. -
Advances in pancreatic cancer treatment.
Taghizadeh H. MEMO. January 2025. DOI: 10.1007/s12254-024-01020-5 -
Perioperative and palliative systemic treatments for biliary tract cancer.
Taghizadeh H, Dong Y, Gruenberger T, Prager GW. Therapeutic Advances in Medical Oncology. March 2024. DOI: 10.1177/17588359241230756 -
Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement
Taghizadeh H, Djanani A, Eisterer W, Gerger A, Gruenberger B, Gruenberger T, Rumpold H, Weiss L, Winder T, Wöll E, Prager GW. Frontiers in oncology. August 2023 -
Austrian tricentric real-life analysis of molecular profiles of metastatic biliary tract cancer patients.
Taghizadeh H, Schmalfuss T, Maj-Hes A, Singer J, Prager GW. Frontiers in Oncology. May 2023. -
Perioperative and palliative systemic treatments for biliary tract cancer.
Taghizadeh H, Dong Y, Gruenberger T, Prager GW. Therapeutic Advances in Medical Oncology. March 2024. DOI: 10.1177/17588359241230756 -
Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors.
Taghizadeh H, Maj-Hes A, Prager GW, Müllauer L, Mader RM. Cancers. April 2022. -
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer.
Taghizadeh H, Prager GW. Current Cancer Drug Targets. February 2022. -
Precision medicine for the management of therapy refractory colorectal cancer.
Taghizadeh H, Mader RM, Müllauer L, Fuereder T, Erhart F, Kautzky-Willer A, Prager GW. Journal of Personalized Medicine. December 2020. -
Molecular guided treatment in metastatic parotid gland carcinoma of adults.
Taghizadeh H, Mader RM, Müllauer L, Fuereder T, Prager GW. Wiener klinische Wochenschrift. December 2020. -
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers.
Taghizadeh H, Mader RM, Müllauer L, Fuereder T, Kautzky-Willer A, Prager GW. Cancers. November 2020. -
Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI.
Taghizadeh H, Unseld M, Spalt M, Mader RM, Müllauer L, Fuereder T, Raderer M, Sibilia M, Hoda MA, Aust S, Polterauer S, Lamm W, Bartsch R, Preusser M, Kautzky-Willer A, Prager GW. Journal of Personalized Medicine. October 2020. -
Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.
Taghizadeh H, Müllauer L, Mader RM, Schindl M, Prager GW. Therapeutic Advances in Medical Oncology. June 2020. -
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Taghizadeh H, Unseld M, Schmiderer A, Djanani A, Wilthoner K, Buchinger D, Prager GW. Cancer Chemotherapy and Pharmacology. May 2020. -
Gender differences in molecular guided therapy recommendations for metastatic malignant mesothelioma.
Taghizadeh H, Zöchbauer-Müller S, Mader RM, Müllauer L, Klikovits T, Bachleitner-Hofmann T, Hoda MAR, Prager GW. Thoracic Cancer. April 2020. -
Personalized adjuvant treatment of colorectal cancer:
Taghizadeh H, Prager GW. Visceral Medicine. April 2020 -
Molecular guided treatments in Gynecologic Oncology - analysis of a real-world precision cancer medicine platform.
Taghizadeh H, Müllauer L, Mader RM, Aust S, Polterauer S, Kölbl H, Seebacher V, Grimm C, Reinthaller A, Prager GW. The Oncologist. March 2020. -
Applied Precision Cancer Medicine in metastatic biliary tract cancer.
Taghizadeh H, Müllauer L, Mader RM, Prager GW. Hepatology International. January 2020 -
Applied Precision Cancer Medicine in Neuro-Oncology.
Taghizadeh H, Müllauer L, Furtner J, Hainfellner JA, Marosi C, Preusser M, Prager GW. Scientific Reports. November 2019 -
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives.
Taghizadeh H, Marhold M, Tomasich E, Udovica S, Merchant A, Krainer M. OncoImmunology. July 2019. - A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors. Taghizadeh H, Lampichler K, Beer A, Preusser M, Ilhan-Mutlu A. MEMO. November 2018.
Further publications can be found in the National Library of Medicine.
Selection of co-authorships
-
Original Research Article: Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.
Reimann P, Mavroeidi IA, Burghofer J, Taghizadeh H et al. Cancer Immunology and Immunotherapy. 2024 October -
Original Research Article: Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study.
Hochmair M, Terbuch A, Lang D, Trockenbacher C, Augustin F, Ghanim B, Maurer D, Taghizadeh H et al. Cancers MDPI. 2024 June -
Original Research Article: Understanding homologous recombination repair (HRR) deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity.
Mavroeidi I, Burghofer J, Kalbourtz S, Taghizadeh H, Webersinke G, Piringer G, Kasper S, Doleschal B. ESMO Open. 2024 June -
Original Research Article: Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
Doleschal B, Taghizadeh H, Lentner T, Riedl JM, Granitzer J, Morariu D, Decker J, Aichberger KJ, Webersinke G, Kirchweger P, Petzer A, Rumpold H. ESMO Open. 2023 Nov -
Original Research Article: Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment.
Doleschal B, Taghizadeh H, Webersinke G, Piringer G, Schreil G, Decker J, Aichberger KJ, Kirchweger P, Thaler J, Petzer A, Schmitt CA, Prager GW, Rumpold H. Sci Rep. 2023 Sep -
Invited short review: Lessons learned in adjuvant colorectal cancer:
Schmalfuss, T., Taghizadeh, H. memo 16, 113-115 (2023). -
Original Research Article: Clinical Characteristics and Comparison of the Outcome in Young versus Older Patients with Upper Gastrointestinal Carcinoma.
Puhr H, Taghizadeh H, Jomrich G, Schoppmann S, Preusser M, Ilhan-Mutlu A. Journal of Cancer Research and Clinical Oncology. June 2020. -
Original Research Article: PD-L1 and HER2 expression in gastroesophageal cancer: a matched case control study.
Beer A, Taghizadeh H, Schoppmann S, Preusser M. Pathology & Oncology Research. April 2020. -
Original Research Article: Comparison of BCR-ABL1 quantification in blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia.
Greiner G, Ratzinger F, Witzeneder N, Taghizadeh H, Mustafa S, Mitterbauer G, Esterbauer H, Mannhalter C, Sperr W, Valent P, Hörmann G. Clinical Chemistry and Laboratory Medicine. January 2020. -
Original Research Article: Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma.
Ruth Baumgartner R; Jomrich G; Taghizadeh H, Schoppmann S; Kain R; Preusser M; Ilhan-Mutlu A. Anticancer Research. January 2020. -
A sex-specific analysis of the predictive value of troponin I and T in patients with and without diabetes mellitus after successful coronary intervention.
Leutner M, Tscharre M, Farhan S, Taghizadeh H, Harreiter J, Vogel B, Tentzeris I, Szekeres T, Fritzer-Szekeres M, Huber K, Kautzky-Willer A. Frontiers in Endocrinology. March 2019, -
Original Research Article: Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis
Bhangu JS, Beer A, Mittlböck M, Tamandl D, Pulverer W, Schönthaler S, Taghizadeh H, Stremitzer S, Kaczirek K, Gruenberger T, Gnant M, Bergmann M, Mannhalter C, Weinhäusel A, Oehler R, Bachleitner-Hofmann T. Annals of Surgery. November 2018. -
Original Research Article: Correlation of Trastuzumab-based Treatment with Clinical Characteristics and Prognosis in HER2 Positive Gastric and gastroesophageal Junction Cancer: A retrospective single center analysis.
Ilhan-Mutlu A, Taghizadeh H, Beer A, Dolak W, Ba-Ssalamah A, Schoppmann SF, Hejna M, Birner P, Preusser M. Cancer Biology and Therapy. March 2018. -
Original Research Article: Circulating cell-free DNA in plasma of colorectal cancer patients- a potential biomarker for tumor burden.
Bhangu JS, Taghizadeh H et al. Surgical Oncology. August 2017.
Further publications can be found in the National Library of Medicine.
Abstract
-
P-132 Daratumumab - a safe first-line treatment of cardiac AL amyloidosis in heavily compromised patients.
Taghizadeh H, Reiter T, Duca F, Binder C, Kornauth C, Agis H The XVIth International Symposium on Amyloidosis March 26-29; Kumamoto, Japan 2018 -
P-99 Likelihood of targeted therapy recommendations for advanced solid tumors.
Taghizadeh H, Müllauer L, Mader RM, Prager G. Annals of Oncology. November 2019. vol. 30vii29 -
P-22 Feasibility of precision cancer medicine in advanced gynecologic cancers.
Taghizadeh H, Prager G, Müllauer L, Mader RM, Aust S, Polterauer S, Reinthaller A, Kölbl H, Seebacher V, Grimm C, Prager G. Annals of Oncology. November 2019. vol. 30vii7 -
P-9 Gender and molecular aspects of molecular-guided therapy recommendations for therapy refractory head and neck cancers.
Taghizadeh H, Müllauer L, Mader RM, Fuereder T, Prager G. Annals of Oncology. October 2020. vol. 31S1219-S1220 -
O-004 Applied precision cancer medicine in advanced biliary tract cancer (oral presentation).
Taghizadeh H, Müllauer L, Mader RM, Prager G. Annals of Oncology. July 2019. vol. 30iv127 -
P-28 Impact of p-mTOR expression on molecular-guided therapy strategies in therapy-refractory metastatic pancreatic ductal adenocarcinoma.
Taghizadeh H, Müllauer L, Mader RM, Prager G. Annals of Oncology. July 2020. vol. 31S98 -
P-48 First evidence for the antitumor activity of nanoliposomal irinotecan in metastatic biliary tract cancer.
Taghizadeh H, Unseld M, Schmiderer A, Buchinger D, Djanani A, Prager G. Annals of Oncology. July 2020. vol. 31S105 -
P-10 Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.
Taghizadeh H, Zöchbauer-Müller S, Mader RM, Müllauer L, Klikovits T, Hoda MA, Bachleitner-Hofmann T, Prager G. Annals of Oncology. October 2020. vol. 31S1220. -
P-1953 Gender and molecular aspects of targeted therapy recommendations for therapy refractory solid tumors: Data from the real-world precision medicine platform MONDTI.
Taghizadeh H, Unseld M, Mader RM, Müllauer L, Fuereder T, Spalt M, Raderer M, Sibilia M, Hoda MA, Aust S, Polterauer S, Lamm W, Bartsch R, Prager G. Annals of Oncology. September 2020. vol. 31S1100 -
P-24 Gender differences in overall survival in patients with metastatic pancreatic cancer.
Taghizadeh H., Wiesholzer M. Annals of Oncology. July 2022. vol.33S255. DOI: https://doi.org/10.1016/j.annonc.2022.04.115 -
P-100 Bicentric real-life analysis of the molecular portrait of patients with metastatic biliary tract cancer.
Schmalfuss T, Prager G, Taghizadeh H. Accepted for ESMO MAP 2022 in Amsterdam, Netherlands -
P-111 Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer.
Schmalfuss T, Prager G, Taghizadeh H. Accepted for ESMO ASIA 2022 in Singapore -
530P - Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study.
A. Seeber1, F. Huemer, B. Doleschal, H. Taghizadeh et al. Annals of Oncology (2024) 35 (suppl_2): S428-S481. 10.1016/annonc/annonc1588 -
1520P - Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis.
Reichinger A., Taghizadeh H. et al. Annals of Oncology (2024) 35 (suppl_2): S923-S936. 10.1016/annonc/annonc1605 -
D33 - Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.
Niedersuess -Beke D., Taghizadeh H. et al. ASCO GU 2025. 10.1200/JCO.2025.43.5_suppl.736 - https://meetings.asco.org/abstracts-presentations/243006
Further publications can be found in the National Library of Medicine.
My research profiles & links to further publications
- https://www.researchgate.net/profile/Hossein-Taghizadeh
- https://kris.kl.ac.at/de/persons/hossein-taghizadeh/publications/
- https://scholar.google.com/citations?user=Ta4FoGQAAAAJ&hl=de
- https://orcid.org/0000-0002-0927-6498
- https://sciprofiles.com/profile/HosseinTaghizadeh
- https://pubmed.ncbi.nlm.nih.gov/?term=Taghizadeh+H&cauthor_id=35168521
My appraisal activities
Peer reviewer for international journals
- Therapeutic Advances in Medical Oncology
- International Journal of Molecular Sciences
- Journal of Personalized Medicine
- Journal of Clinical Medicine
- Frontiers in Oncology
- Molecular Oncology
- Cancer Control
- Diagnostics
- Genes
Appraiser
- Expert at the Austrian Society for Hematology & Medical Oncology (OeGHO)
- Expert at the Medical-Scientific Fund of the City of Vienna
Services
Prompt appointment allocation
Both personal and virtual consultation possible
Clarification of anemia and unclear blood findings
Advice on concomitant medication
Detailed consultation and second opinion for unclear and difficult cases, especially solid tumors
Advice on preventive care, especially for high-risk patients
Regular aftercare
Further services
Oncological nutritional advice
Bloodletting, especially for patients with polyglobulia
Infusion therapy to correct electrolyte, vitamin and iron deficiencies
Ascites puncture directly in the surgery room
Treatment of nausea with modern antiemetic therapy
Internal surgery clearance, especially for patients with cancer
Pain counseling and pain therapy, especially for patients with cancer
Adjustment of blood sugar and blood pressure, especially in patients with cancer
Shock wave therapy for polyneuropathy, chronic pain and wound healing disorders
Examination with ultrasound (sonography)
12-lead ECG
Prices
The fee for the initial consultation with detailed clarification, discussion of findings and treatment proposal is EUR 300.
The fee for re-presentations is EUR 200.
The prices for the individual services will be agreed with you individually depending on the work involved.
Payment can be made in cash, by debit or credit card or by bank transfer.
Your advantages
in my private practice
Accessibility
Barrier-free / wheelchair-accessible facilities and toilet
Pharmacy
The private practice is located directly above a large pharmacy
(Bartholomäus-Apotheke)
Parking lots
Free parking in the Hernals shopping center for 2 hours
Central location
Easy to reach with streetcar lines 9 and 43
